Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Andorsky

Interim Analysis of Phase Iiib Magnify Study of Induction R2 Followed by Maintenance in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Hematological Oncology

English

Related publications

Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Hematological Oncology

English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology

English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology

English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology

English

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

Hematological Oncology

English

Interim Data From the First Clinical Study of Adct-301, a Novel Pyrrolobenzodiazapine-Based Antibody Drug Conjugate, in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Hematological Oncology

English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie

Oncology

2016

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Andorsky

Interim Analysis of Phase Iiib Magnify Study of Induction R2 Followed by Maintenance in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Related publications

Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

Interim Data From the First Clinical Study of Adct-301, a Novel Pyrrolobenzodiazapine-Based Antibody Drug Conjugate, in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma